A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The overall objective of the study is to assess the effectiveness of switching from immediate-release prednisone (conventional) therapy to delayed-release prednisone (RAYOS) in patients with moderately to severely active Rheumatoid Arthritis (RA), managed according to standard of care in clinical practice settings.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Horizon Pharma Ireland, Ltd., Dublin Ireland
• Treatments: Prednisone

Criteria

Inclusion Criteria:

• Age ≥ 18 and in general good health (Investigator discretion) with a recent stable medical history other than related to RA disease activity

• RA diagnosis is ≥ 6 months according to ACR and/or EULAR classification criteria for diagnosis of active RA

• Morning stiffness duration of at least 45 minutes at study entry

• RA disease activity as defined by DAS28 of ≥ 3.2 at study entry

• Currently receiving conventional immediate-release prednisone ≥ 2.5 milligram (mg) every morning and previously agreed to switch to RAYOS

• Willing and able to sign an Informed Consent Form (ICF)

Exclusion Criteria:

• Patient is unwilling to participate in the non-interventional study